Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926197 | PMC |
| http://dx.doi.org/10.1002/ajh.25032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
J Thromb Haemost
November 2023
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Cardiology, Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust, Birmingham, United Kingdom; Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Electronic address:
Background: Aspirin and platelet P2Y inhibitors, such as ticagrelor, suboptimally inhibit microvascular thrombosis during ST-elevation myocardial infarction. Glycoprotein (GP) IIb/IIIa inhibitors may further inhibit this but cause excessive bleeding.
Objectives: We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in hemostasis.
Cryo-EM structures of full-length integrin αIIbβ3 in native lipids.
Nat Commun
July 2023
Leukocyte Biology and Inflammation Laboratory, Structural Biology Program, Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA.
Article Synopsis
- *Anti-αIIbβ3 drugs like eptifibatide can prevent blood clots but may also hinder normal blood clotting functions.
- *New cryo-EM structures reveal the full-length integrin's features, showing surprising accessibility of the ligand-binding site and significant changes when eptifibatide is bound, providing insights for safer drug development.*
Uncoupling of platelet granule release and integrin activation suggests GPIIb/IIIa as a therapeutic target in COVID-19.
Blood Adv
June 2023
Institute of Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany.
Thromboembolic events are frequent and life-threating complications of COVID-19 but are also observed in patients with sepsis. Disseminated thrombosis can occur despite anticoagulation, suggesting that platelets play a direct but incompletely understood role. Several studies demonstrated altered platelet function in COVID-19 with some controversial findings, while underlying disease-specific mechanisms remain ill defined.
View Article and Find Full Text PDFIdentification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using Structure-Based Virtual Screening Approach.
Front Immunol
August 2020
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India.
The rapidly spreading, highly contagious and pathogenic SARS-coronavirus 2 (SARS-CoV-2) associated Coronavirus Disease 2019 (COVID-19) has been declared as a pandemic by the World Health Organization (WHO). The novel 2019 SARS-CoV-2 enters the host cell by binding of the viral surface spike glycoprotein (S-protein) to cellular angiotensin converting enzyme 2 (ACE2) receptor. The virus specific molecular interaction with the host cell represents a promising therapeutic target for identifying SARS-CoV-2 antiviral drugs.
View Article and Find Full Text PDFAlphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection.
Antiviral Res
July 2020
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, 247667, Uttarakhand, India. Electronic address:
Chikungunya virus (CHIKV) is an arthritogenic alphavirus and currently, no antiviral drug is available to combat it. Capsid protein (CP) of alphaviruses present at the N-terminus of the structural polyprotein possesses auto-proteolytic activity which is essential for initiating the structural polyprotein processing. We are reporting for the first time antiviral molecules targeting capsid proteolytic activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!